Pfizer Inc. logo
Pfizer Inc. (PFE)
Compare

Pfizer Inc. (PFE) PS Ratio: 2.32

Is Pfizer Inc.’s P/S ratio high or low?

Pfizer Inc.'s P/S ratio of 2.32 is 19% below its 5-year average of 2.86, near the low end of its 5-year range (1.94–5.89).

The P/S ratio for Pfizer Inc. (PFE) is 2.32 as of Wednesday, June 10, 2026. It is above its 12-month average by 0.01% (2.32).

PFE PS Ratio Chart

PFE PS Ratio
2.32+4.50% 1Y
Zoom

PFE Average PS Ratio Chart

PFE Current vs Average PS Ratio Chart

PFE PS Ratio Metrics

PS RATIO

2.32

PS RATIO AVG TTM

2.32

PS RATIO AVG 3Y

2.45

PS RATIO AVG 5Y

2.86

PS RATIO AVG 10Y

3.47

PS RATIO AVG 15Y

3.42

PS RATIO AVG 20Y

3.23

CURRENT VS TTM AVG

+0.01%

CURRENT VS 3Y AVG

-5.17%

CURRENT VS 5Y AVG

-18.95%

CURRENT VS 10Y AVG

-33.17%

CURRENT VS 15Y AVG

-32.21%

CURRENT VS 20Y AVG

-28.24%

PFE Competitors' PS Ratio

NAMEMARKET CAPPS RATIOTTM3Y5Y
Pfizer Inc. (PFE)2.322.322.452.86
Intuitive Surgical, Inc. (ISRG)$146.44B14.0718.7319.8819.01
Gilead Sciences, Inc. (GILD)$151.21B5.135.414.323.91
Abbott Laboratories (ABT)$154.66B3.444.754.814.78
Danaher Corporation (DHR)$130.25B5.296.026.596.43
CVS Health Corporation (CVS)$125.16B0.310.250.240.31
Bristol-Myers Squibb Company (BMY)$114.14B2.362.212.312.70
Thermo Fisher Scientific Inc. (TMO)$179.45B3.994.394.674.97
Vertex Pharmaceuticals Incorporated (VRTX)$110.77B9.149.6810.549.74
Amgen Inc. (AMGN)$183.75B4.974.895.135.11

P/S vs. its own history

At 2.32, P/S is cheaper than usual — richer than 20% of its 20-year range.

20-year low

1.57

median

3.39

20-year high

5.89

cheaperricher

Sales Valuation

P/S Ratio

2.32

Market Cap / Annual Revenue

Pfizer Inc. PS Ratio Formula & Definition

PS Ratio = Market Cap / Revenue (TTM)

The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Pfizer Inc. PS Ratio FAQ

What is the P/S ratio for Pfizer Inc. (PFE)?
The P/S ratio for PFE stock is 2.32.
Is Pfizer Inc.'s P/S ratio high or low?
Pfizer Inc.'s P/S ratio of 2.32 is 19% below its 5-year average of 2.86, near the low end of its 5-year range (1.94–5.89).
What is the TTM average P/S ratio for Pfizer Inc. (PFE)?
The TTM average P/S ratio for PFE stock is 2.32.
What is the 3Y average P/S ratio for Pfizer Inc. (PFE)?
The 3Y average P/S ratio for PFE stock is 2.45.
What is the 5Y average P/S ratio for Pfizer Inc. (PFE)?
The 5Y average P/S ratio for PFE stock is 2.86.
What is the 10Y average P/S ratio for Pfizer Inc. (PFE)?
The 10Y average P/S ratio for PFE stock is 3.47.
What is the 15Y average P/S ratio for Pfizer Inc. (PFE)?
The 15Y average P/S ratio for PFE stock is 3.42.
What is the 20Y average P/S ratio for Pfizer Inc. (PFE)?
The 20Y average P/S ratio for PFE stock is 3.23.

Pfizer Inc. PS Ratio History

DATEPS RATIO
2026-06-102.32
2026-06-092.33
2026-06-082.32
2026-06-052.36
2026-06-042.33
2026-06-032.29
2026-06-022.31
2026-06-012.32
2026-05-292.37
2026-05-282.37
2026-05-272.37
2026-05-262.34
2026-05-222.34
2026-05-212.35
2026-05-202.33
2026-05-192.32
2026-05-182.29
2026-05-152.29
2026-05-142.33
2026-05-132.35
2026-05-122.34
2026-05-112.34
2026-05-082.32
2026-05-072.40
2026-05-062.40
2026-05-052.39
2026-05-042.39
2026-05-012.39
2026-04-302.43
2026-04-292.39
2026-04-282.41
2026-04-272.43
2026-04-242.45
2026-04-232.42
2026-04-222.44
2026-04-212.48
2026-04-202.50
2026-04-172.50
2026-04-162.47
2026-04-152.47
2026-04-142.46
2026-04-132.48
2026-04-102.45
2026-04-092.47
2026-04-082.50
2026-04-072.46
2026-04-062.53
2026-04-022.57
2026-04-012.59
2026-03-312.55
2026-03-302.52
2026-03-272.46
2026-03-262.51
2026-03-252.48
2026-03-242.45
2026-03-232.43
2026-03-202.45
2026-03-192.49
2026-03-182.48
2026-03-172.49
2026-03-162.42
2026-03-132.42
2026-03-122.44
2026-03-112.48
2026-03-102.47
2026-03-092.44
2026-03-062.46
2026-03-052.42
2026-03-042.42
2026-03-032.42
2026-03-022.48
2026-02-272.51
2026-02-262.46
2026-02-252.47
2026-02-242.47
2026-02-232.46
2026-02-202.43
2026-02-192.44
2026-02-182.49
2026-02-172.49
2026-02-132.51
2026-02-122.50
2026-02-112.52
2026-02-102.51
2026-02-092.46
2026-02-062.48
2026-02-052.41
2026-02-042.44
2026-02-032.35
2026-02-022.43
2026-01-302.41
2026-01-292.38
2026-01-282.35
2026-01-272.41
2026-01-262.36
2026-01-232.33
2026-01-222.38
2026-01-212.36
2026-01-202.32
2026-01-162.33
2026-01-152.36
2026-01-142.33
2026-01-132.29
2026-01-122.30
2026-01-092.32
2026-01-082.30
2026-01-072.30
2026-01-062.31
2026-01-052.29
2026-01-022.29
2025-12-312.27
2025-12-302.27
2025-12-292.28
2025-12-262.28
2025-12-242.28
2025-12-232.26
2025-12-222.29
2025-12-192.29
2025-12-182.28
2025-12-172.28
2025-12-162.32
2025-12-152.41
2025-12-122.35
2025-12-112.35
2025-12-102.35
2025-12-092.31
2025-12-082.35
2025-12-052.37
2025-12-042.34
2025-12-032.33
2025-12-022.29
2025-12-012.30
2025-11-282.34
2025-11-262.34
2025-11-252.34
2025-11-242.30
2025-11-212.28
2025-11-202.22
2025-11-192.26
2025-11-182.32
2025-11-172.28
2025-11-142.28
2025-11-132.35
2025-11-122.35
2025-11-112.32
2025-11-102.22
2025-11-072.22
2025-11-062.26
2025-11-052.24
2025-11-042.21
2025-11-032.20
2025-10-312.20
2025-10-302.17
2025-10-292.17
2025-10-282.19
2025-10-272.21
2025-10-242.21
2025-10-232.21
2025-10-222.21
2025-10-212.22
2025-10-202.21
2025-10-172.19
2025-10-162.17
2025-10-152.18
2025-10-142.19
2025-10-132.21
2025-10-102.22
2025-10-092.26
2025-10-082.30
2025-10-072.35
2025-10-062.36
2025-10-032.45
2025-10-022.42
2025-10-012.43
2025-09-302.28
2025-09-292.13
2025-09-262.12
2025-09-252.11
2025-09-242.15
2025-09-232.16
2025-09-222.15
2025-09-192.15
2025-09-182.16
2025-09-172.15
2025-09-162.14
2025-09-152.14
2025-09-122.13
2025-09-112.22
2025-09-102.20
2025-09-092.21
2025-09-082.19
2025-09-052.22
2025-09-042.19
2025-09-032.22
2025-09-022.23
2025-08-292.21
2025-08-282.20
2025-08-272.24
2025-08-262.23
2025-08-252.25
2025-08-222.31
2025-08-212.30
2025-08-202.27
2025-08-192.26
2025-08-182.24
2025-08-152.25
2025-08-142.24
2025-08-132.25
2025-08-122.20
2025-08-112.20
2025-08-082.20
2025-08-072.17
2025-08-062.14
2025-08-052.21
2025-08-042.15
2025-08-012.15
2025-07-312.13
2025-07-302.18
2025-07-292.22
2025-07-282.22
2025-07-252.27
2025-07-242.32
2025-07-232.32
2025-07-222.30
2025-07-212.22
2025-07-182.24
2025-07-172.25
2025-07-162.25
2025-07-152.25
2025-07-142.32
2025-07-112.34
2025-07-102.36
2025-07-092.34
2025-07-082.34
2025-07-072.31
2025-07-032.32
2025-07-022.31
2025-07-012.29
2025-06-302.22
2025-06-272.21
2025-06-262.22
2025-06-252.22
2025-06-242.22
2025-06-232.20
2025-06-202.19
2025-06-182.18
2025-06-172.19
2025-06-162.23
2025-06-132.24
2025-06-122.27
2025-06-112.24
2025-06-102.22
2025-06-092.19
2025-06-062.13
2025-06-052.11
2025-06-042.14
2025-06-032.13
2025-06-022.14
2025-05-302.15
2025-05-292.14

Showing the most recent 260 of 5,031 data points. The chart above shows the full history.

About Pfizer Inc.

Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.

New York City, NY
81,000 employees
Healthcare / Drug Manufacturers - General
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Albert Bourla